Navigation Links
Novelos Therapeutics Announces Encouraging Results in Ongoing Phase,2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care

NEWTON, Mass.--(BUSINESS WIRE)--Jun 18, 2007 - Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced encouraging results in an ongoing Dana-Farber/Partners Cancer Care (DF/PCC) Phase 2 trial of NOV-002 in combination with carboplatin in platinum-resistant ovarian cancer patients. To date, 10 patients were evaluable for best overall tumor response (assessed at least after 8 weeks / 2 chemotherapy cycles), whereby all 10 women had previously failed three lines of chemotherapy (starting fourth line). 1 patient had a partial response, 5 stable disease and 4 progressive disease. NOV-002 was well-tolerated, further extending the excellent safety profile NOV-002 has demonstrated in previous studies.

The primary objective of this open-label single-arm Phase 2 is to determine the tumor response rate in a cohort of women with platinum-resistant ovarian cancer after treatment with NOV-002 and carboplatin. Up to 25 women may be enrolled in the trial and may receive up to six cycles of NOV-002 and carboplatin. A link to the trial description and contact information is available at under 'Clinical Trials' section.

"I am encouraged by these preliminary results in platinum-resistant ovarian cancer, with NOV-002 (in combination with carboplatin) apparently slowing disease progression in over half of the treated patients," said Dr. Carolyn Krasner, the Principal Investigator. "Most women, having failed three lines of chemotherapy, would be expected to progress in about eight weeks."

"We look forward to continuing to work closely with Dana-Farber/Partners on developing NOV-002 for this indication," said Harry Palmin, President and CEO of Novelos. "Meanwhile, Novelos remains on-track for full enrollment of our pivotal Phase 3 trial of NOV-002 for lung cancer in the first quarter 2008."

Acco rding to the American Cancer Society, in 2006 approximately 20,000 U.S. women were expected to be diagnosed with ovarian cancer and 15,000 women were expected to die from it. There is a lack of effective treatment, particularly in the case of platinum-resistant patients. Once a woman's ovarian cancer is defined as platinum-resistant the chance of having a partial or complete response to further platinum therapy is typically less than 10%. Thus, there is a major unmet medical need for this indication.

About Dana-Farber/Partners CancerCare (DF/PCC)

DF/PCC is a joint venture non-profit consortium established by Massachusetts General Hospital, Brigham and Women's Hospital and Dana-Farber Cancer Institute. The clinical research efforts of this consortium are organized through Disease Programs. The Gynecologic Cancer Program focuses on the evaluation of novel therapeutic strategies in the treatment of women with gynecologic malignancies and in particular ovarian cancer.

About Novelos Therapeutics, Inc.

Novelos Therapeutics, Inc. is a biopharmaceutical company commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. NOV-002, the lead compound currently in Phase 3 development for lung cancer under a SPA and Fast Track, acts together with chemotherapy as a chemoprotectant and an immunomodulator. NOV-002 is also in Phase 2 development for chemotherapy-resistant ovarian cancer and early-stage breast cancer, and is in addition being developed for acute radiation injury. NOV-205 acts as a hepatoprotective agent with immunomodulating and anti-inflammatory properties. NOV-205 is in Phase 1b development for chronic hepatitis C non-responders. Both compounds have completed clinical trials in humans and have been approved for use in the Russian Federation where they were originally developed. For additional information about Novelos please visit Novelos Therapeutics, Inc. One Gateway Center, Suite 504 Newton, MA 02458

This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement.


Novelos Therapeutics, Inc.
Harry S. Palmin, President and CEO, 617-244-1616 x11
Investor Relations
Stephen Lichaw, 201-240-3200


Related medicine technology :

1. Novelos Therapeutics and MUSC Present Two Posters at AACR 2007 Annual Meeting
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:11/26/2015)... Países Bajos, November 26, 2015 ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... con la terapia fotodinámica de Bremachlorin para el cáncer ... enfoque combina la inmunoterapia con la terapia fotodinámica de ... Clinical Cancer Research . --> Clinical Cancer ...
(Date:11/26/2015)... 26, 2015 ... aanpak combineert immunotherapie met Bremachlorin-photodynamische therapie voor ... ) --> ... ) Uit ... Centrum (LUMC) blijkt ...
(Date:11/26/2015)... 2015 3D bioprinting market is ... a new report by Grand View Research Inc. Rising prevalence ... demands kidney transplantation is expected to boost the market growth, ... organ transplantation. --> 3D bioprinting market is ... a new report by Grand View Research Inc. Rising prevalence ...
Breaking Medicine Technology:
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... a real-time eReferral system for diagnostic imaging in the Waterloo region. Using the ... and Nuclear Medicine tests directly from their electronic medical record (EMR) without the ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent ... and the need to integrate dose form selection in early phase drug development. ... membership organization supporting and bringing together the UK’s emerging life sciences companies, corporate ...
(Date:11/26/2015)... ... 2015 , ... PRMA Plastic Surgery is updating their record books yet again ... free flap breast reconstruction surgery! , “What an accomplishment for the PRMA team, says ... and it’s an honor to have served all of these women.” , PRMA is ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film Studios brings ... with ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired ... font, giving users limitless opportunities to stylize and create designs quickly and easily, ...
(Date:11/26/2015)... ... November 26, 2015 , ... Indosoft Inc., developer and distributor ... application server to improve system efficiency and reliability. , The new Q-Suite 6 platform ... standards, the system avoids locking itself into a specific piece of software for many ...
Breaking Medicine News(10 mins):